<DOC>
	<DOCNO>NCT01502020</DOCNO>
	<brief_summary>Zyclara™ ( imiquimod ) Cream , 3.75 % approve FDA treatment actinic keratoses full face bald scalp . Zyclara apply daily two , 2-week treatment cycle separate 2-week treatment apply interval . A generic imiquimod cream , 3.75 % developed Actavis Mid-Atlantic LLC topical treatment clinically typical , visible palpable actinic keratoses ( AK ) full face bald scalp . The current clinical study design evaluate therapeutic equivalence formulation currently market Zyclara™ ( imiquimod ) cream , 3.75 % formulation ( Graceway Pharmaceuticals LLC ) .</brief_summary>
	<brief_title>A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream , 3.75 % Zyclara™ ( Imiquimod ) Cream , 3.75 % Subjects With Actinic Keratoses</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Subject male female , 18 year age old . Subject provide write informed consent . Subject willing able apply test article direct , comply study instruction commit followup visit duration study . Subject clinical diagnosis actinic keratoses ( AK ) least five ( 5 ) 20 clinically typical , visible palpable AK lesion , least 4mm diameter , area great 25cm2 face ( exclude ear ) bald scalp , . Subject good general health free disease state physical condition might impair evaluation AK lesion , investigator 's opinion , expose subject unacceptable risk study participation . If subject woman childbearing potential ( WOCBP ) , must negative urine pregnancy test ( UPT ) agree use effective form birth control duration study ( e.g. , abstinence , stabilize hormonal contraceptive least three month [ oral , implant , injection , IUD , patch NuvaRing ] condom spermicidal diaphragm spermicidal ) . Abstinence acceptable form birth control subject sexually active . Subjects become sexually active trial agree use effective , nonprohibited form birth control duration study . Subject pregnant , lactating , plan become pregnant study . Subjects hyperkeratotic , hypertrophic atypical AKs ( e.g. , AK &gt; 1 cm2 size ) Treatment Area . Subject enrol investigational drug device study study period . Subject planning expose artificial tanning device excessive sunlight trial . Subject immunosuppressed ( e.g. , HIV , systemic malignancy , graft vs. host disease , etc. ) . Subject experienced unsuccessful outcome previous imiquimod therapy ( An unsuccessful outcome define reasonable therapeutic trial compliance issue , topical application work ) . Subject used investigational drug investigational device within 30 day prior Baseline Visit . Subject laser resurfacing , PUVA ( Psoralen + ultraviolet A ) therapy , UVB therapy , chemical peel dermabrasion face bald scalp within 6 month prior Baseline Visit . Subject cryodestruction chemodestruction , curettage , photodynamic therapy , surgical excision treatment actinic keratosis face scalp within one month prior Baseline Visit . Subject use oral corticosteroid therapy , interferon , cytotoxic drug , immunomodulators , immunosuppressive therapy retinoids within one month prior Baseline Visit . Subject use topical medication , corticosteroid , alpha hydroxy acid ( e.g. , glycolic acid , lactic acid etc . &gt; 5 % ) , beta hydroxy acid ( salicylic acid &gt; 2 % ) , urea &gt; 5 % , 5fluorouracil , diclofenac , imiquimod prescription retinoids ( e.g. , tazarotene , adapalene , tretinoin ) face bald scalp within one month prior Baseline Visit . Subject use topical cream , lotion gel kind select Treatment Area within one day prior Baseline Visit . Subject basal cell squamous cell carcinoma within Treatment Area within one year study enrollment . Subject history sensitivity ingredient test article . Subject skin pathology condition ( e.g. , facial/scalp psoriasis , atopic dermatitis , acne , rosacea , etc . ) , investigator 's opinion , could interfere evaluation test article , worsen due treatment require use interfere topical , systemic surgical therapy . Subject condition , investigator 's opinion , would make unsafe precluded subject 's ability fully participate research study . Subject know noncompliant unlikely comply requirement study protocol ( e.g. , due alcoholism , drug dependency , mental incapacity ) opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>actinic keratoses</keyword>
	<keyword>actinic keratosis</keyword>
	<keyword>imiquimod , 3.75 %</keyword>
	<keyword>imiquimod</keyword>
	<keyword>Zyclara</keyword>
	<keyword>Actinic keratoses face bald scalp</keyword>
</DOC>